Asciminib Continues to Demonstrate Superior Efficacy for CML-CP
The patients were randomly assigned 2:1 to asciminib 40 mg twice daily or bosutinib 500 mg once daily.
Chronic Myeloid Leukemia News
CHRONIC MYELOID LEUKEMIA ADVISOR
Chronic Myeloid Leukemia News
Longer Deep Molecular Remission in CML Associated With Treatment-Free Remission
The investigators performed univariate and multivariate analyses to identify factors associated with the loss of MMR.
Use of Oral Tyrosine Kinase Inhibitors for R/R CML Increasing Over Time
From 2017 to 2019, the number of beneficiaries prescribed at least 1 oral TKI increased from 154 beneficiaries to 212 beneficiaries.
CML Does Not Affect Antibody Development Against SARS-CoV-2
Investigators reported findings from the ongoing SARS2 SeroPrevalence And Respiratory Tract Assessment (SPARTA) study.
Trends in Second Malignancy and Mortality Risk After Primary Chronic Myeloid Leukemia
In CML, second malignancies are rare and trends remain poorly understood.
Guidelines for CML Not Followed in the Real World
“Excellent” overall survival is achievable with currently available drugs, according to researchers.
Two-Step Strategy Promising in TKI Dose Reduction in Chronic Myeloid Leukemia
The likelihood of recovery of major molecular response after resuming TKI therapy at reduced doses was 86%.
Platelet, Hemoglobin Levels Related to COVID-19 Mortality in Hematologic Malignancies
A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
Chronic Myeloid Leukemia: 5 Myths You May Encounter
Patients may not have much information on chronic myeloid leukemia, and some may have a number of misunderstandings surrounding the condition. As a health care professional, what are some of these myths you can correct to better educate patients?
Duration of TKI Treatment Predicts Early, Late Recurrence in Chronic Myeloid Leukemia
The underlying mechanisms of late recurrence must be investigated further, according to researchers.
Many Oncology Drugs Approved for Genomic Indications Not Studied for Overall Survival Outcomes
Overall survival data were available for about half of the drugs.
Asciminib Continues to Demonstrate Superior Efficacy vs Bosutinib in Chronic Phase Chronic Myeloid Leukemia
Updated data demonstrated asciminib significantly improved the rate of MMR at 48 weeks compared with bosutinib.
Seroconversion After COVID-19 Vaccination High in CML, Low in NHL
Seroconversion was observed in 99% of patients with chronic myeloid leukemia.
Ankle-Brachial Index, Cardiac Ankle Vascular Index May Indicate Risk of Cardiovascular AEs in Patients With CML Taking TKIs
A retrospective analysis of data identified predictors of cardiac adverse events in patients with CML undergoing treatment with tyrosine kinase inhibitors.
Factors That Impact HRQOL in Pediatric Patients With Chronic Myeloid Leukemia
Patients’ age, sex, and treatment-related symptoms, as well as mothers’ education level, were significantly associated with HRQOL.
Comparison of Generic and Branded Imatinib for Patients With Chronic Myeloid Leukemia
Researchers sought to determine whether there was a difference in generic or branded imatinib in treating patients with CML.
Scemblix Approved for Ph+ Chronic Myeloid Leukemia in Chronic Phase
Asciminib inhibits the ABL1 kinase activity of the BCRABL1 fusion protein, by binding to the ABL myristoyl pocket.
Algorithm Assesses Risk of Major Adverse Cardiovascular Events in TKI-Treated CML
Researchers sought to determine the accuracy of established tools in predicting the risk of cardiovascular events in patients with CML receiving TKIs.
Survey Reveals ‘Striking’ Barriers to Accessing High-Priority Cancer Drugs
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
PTSD in Cancer Patients: What Providers Need to Know
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...